Purple Biotech (PPBT) Total Liabilities (2017 - 2021)

Purple Biotech (PPBT) has disclosed Total Liabilities for 5 consecutive years, with $5.1 million as the latest value for Q4 2021.

  • On a quarterly basis, Total Liabilities rose 25.7% to $5.1 million in Q4 2021 year-over-year; TTM through Dec 2021 was $5.1 million, a 25.7% increase, with the full-year FY2021 number at $5.1 million, up 25.7% from a year prior.
  • Total Liabilities was $5.1 million for Q4 2021 at Purple Biotech, up from $4.1 million in the prior quarter.
  • In the past five years, Total Liabilities ranged from a high of $5.1 million in Q4 2021 to a low of -$8.7 million in Q4 2017.
  • A 5-year average of $1.6 million and a median of $3.9 million in 2019 define the central range for Total Liabilities.
  • Peak YoY movement for Total Liabilities: soared 142.81% in 2018, then increased 3.76% in 2019.
  • Purple Biotech's Total Liabilities stood at -$8.7 million in 2017, then skyrocketed by 142.81% to $3.7 million in 2018, then rose by 3.76% to $3.9 million in 2019, then grew by 4.98% to $4.1 million in 2020, then increased by 25.7% to $5.1 million in 2021.
  • Per Business Quant, the three most recent readings for PPBT's Total Liabilities are $5.1 million (Q4 2021), $4.1 million (Q4 2020), and $3.9 million (Q4 2019).